Share this page: More
 

Kristin L. Bigos

Richard Ambinder 

Department Affiliation: Primary: Medicine, Division of Clinical Pharmacology; Secondary: Pharmacology and Molecular Sciences, Psychiatry and Behavior Sciences
Degree: Ph.D., University of Pittsburgh, School of Pharmacy
Rank: Assistant Professor
Telephone Number: 410-614-0453
Fax Number: 410-614-9978
E-mail address: kbigos1@jhu.edu
School of Medicine Address: Osler 503, 600 N. Wolfe Street, Baltimore, MD 21287
Website:  Bigos Hopkinsmedicine Webpage

 

Using neuroimaging and genetics to develop better drugs for psychiatry 

The Bigos Lab uses functional MRI as a biomarker to test the neural effects of drugs designed to treat symptoms of mental illness.  Her lab currently has a pharmacoMRI study to develop a treatment for cognitive dysfunction in schizophrenia. Other studies aim to identify patient-specific variables including sex, race, and genetics that impact drug clearance and clinical response to better select and dose antipsychotics and antidepressants.


Representative Publications:

  • Bigos, K.L., Mattay, V.S., Callicott, J.H., Straub, R.E., Vakkalanka, R., Kolachana, B., Hyde, T.M., Lipska, B.K., Kleinman, J.E., Weinberger, D.R. Genetic Variation in CACNA1C Affects Brain Circuitries Related to Mental Illness. Arch Gen Psychiatry 2010; 67(9):939-45. Pub Med Reference
  • Heide, J., Zhang, F., Bigos, K.L., Mann, S.A., Carr, V.J., Shannon-Weickert, C., Green, M.J., Weinberger, D.R., Vandenberg, J.I. Differential response to antipsychotics in schizophrenia patients with KCNH2 risk alleles is correlated with affinities for the Kv11.1-3.1 potassium channel. Am J Psychiatry. 2016;173(1):53-59Pub Med Reference
  • Bigos, K.L., Bies, R.R., Pollock, B.G., Lowy, J.J., Zhang, F., Weinberger, D.R. Genetic Variation in CYP3A43 Explains Racial Difference in Olanzapine Clearance. Molecular Psychiatry. 2011; 16:620-625.  Pub Med Reference   
  • Dickinson, D., Straub, R.E., Trampush, J., Gao, Y., Feng, N.. Xie, B., Shin, J.H., Lim, H.K. Callicott, J.H., Bigos, K.L., Kolachana, B., Hashimoto, R., Takeda, M., Rujescu, D., Hyde, T.M., Berman, K.F., Kleinman, J.E., Weinberger, D.R. Interaction of common variants in SCN2A with schizophrenia and general cognitive ability, brain physiology and mRNA expression in brain. JAMA Psychiatry. 2014;71(6):647-56. Pub Med Reference
  • Bigos, K.L., Pollock, B.G., Aizenstein, H.J., Fisher, P.M., Bies, R.R., Hariri, A.R. Acute 5-HT Reuptake Blockade Potentiates Human Amygdala Reactivity. Neuropsychopharmacology 2008; 33:3221-3225. Pub Med Reference  

 

 


Other graduate programs in which Dr. Bigos participates:  None